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1607-551X/Copyright ª 2015, KaohsiuAbstract The aim of this study was to quantify the hormone therapy (HT) nonadherence pat-
terns and to assess the associated risk factors in Asian women with breast cancer. This retro-
spective cohort study used the Taiwan Health Insurance Research Database from 2003 to 2011.
Data from women with newly diagnosed primary breast cancer were identified, and persis-
tence (without HT prescribing gap  180 days) to HTwas defined through records of dispensing
prescriptions. Study cohorts were further classified as adjuvant and primary HT groups. Each
individual’s HT utilization patterns and the medication possession ratio at overall HT course
were measured. The odds ratios (ORs) of nonadherence (medication possession ratio, <80%)
in adjuvant and primary HT patients were estimated using logistic regressions with adjustment
of potential confounding variables. These patients had 15.6% and 23.4% nonadherence rates to
HT in adjuvant and primary HT groups, respectively. In the adjuvant HT group, older age groups
(50 years) and taking aromatase inhibitors were less likely to show nonadherence (p < 0.05).
In the primary HT group, women older than 70 years were significantly less likely to exhibit
nonadherence (OR Z 0.53; 95% confidence interval, 0.28e0.99); however, women with pres-
ence of HT-related adverse events had significantly increased risk (ORZ 1.44; 95% confidence
interval, 1.02e2.03). Young age and experience of musculoskeletal and joint symptoms were
identified as risk factors for nonadherence.
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reserved.eclare no conflicts of interest.
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Hormone therapy nonadherence and risks 329Introduction
Nonadherence to long-term pharmacotherapy is a key
concern of treating chronic diseases. It is associated with
suboptimal treatment outcomes, and consequently in-
creases medication utilization [1,2]. In the past, non-
adherence was not the major issue of interest in cancer
treatment, and most oncology therapies were adminis-
tered by health care professionals in secondary care [3].
With recent developments in oncology, cancer survival has
been improved and more oral therapies are available on
the market for long-term control of cancers. The adher-
ence and persistence to long-term oral anticancer therapy
have become key factors to ensure therapeutic outcomes
[4,5].
Although a 5-year course of adjuvant hormone therapy
(HT), including tamoxifen and aromatase inhibitors (AIs),
has proven effective in reducing recurrence and mortality
in hormone-sensitive breast cancer (BC) [6], current evi-
dence has indicated that HT adherence was suboptimal
[7e9]. Nonadherence to HT could lead to an increase in
mortality of women with BC [10e13]. The majority of
evidence on detrimental BC outcomes associated with
non-adherence to HT is predominately based on research
from Western countries, where the peak age of BC diag-
nosis (60e70 years) is about 10 years older than those
from Asian countries (40e50 years) [14]. Our previous
study results found that interruption and nonadherence to
adjuvant HT were significantly associated with increased
mortality, which was one of the few studies conducted in
an Asian population [12]. Furthermore, we also demon-
strated that the 5-year cumulative incidence of first HT
interruption was 13%, as estimated using the competing
risk methods [15]. The remaining issue will be to evaluate
the adherence pattern in the long-term utilization of HT in
this population.
Adherence is a complex and multifaceted issue associ-
ated with a variety of factors influencing patients’
medication-taking behaviors. Currently, there is no gold
standard to measure adherence in clinical practice and no
exclusively operational definition of good adherence
[16,17]. The medication possession ratio (MPR) is a com-
mon measure of adherence in longitudinal studies;
conventionally, an MPR < 80% is considered nonadherence
[18,19]. The nonadherence rate of HT changes over time
and may be influenced by multiple factors, such as the
improvement in symptoms or the experiencing of adverse
effects [20].
In Taiwan, agents of HT are available for women with
BC under the coverage of the Taiwan National Health In-
surance (NHI) Program, which was established in 1995,
providing comprehensive medical care for 99.6% of the
entire population (23.74 million) in 2010 [21]. Tamoxifen is
normally the agent of choice, and treatment with AIs is
reimbursed under a set of criteria. Studies on HT utiliza-
tion and the impacts of HT nonadherence on BC treatment
in Taiwan have not been fully investigated. Accordingly,
this study aimed to quantify the HT nonadherence pat-
terns and assess the associated risk factors, as seen in an
Asian population.Methods
Study design and data source
This retrospective cohort study used the Taiwan National
Health Insurance Research Database (NHIRD) as a
population-based reimbursement dataset from 2003 to
2011. Data of all BC patients, including outpatient and
inpatient medical claims, dispensing claims from commu-
nity pharmacies, and the Registry for Catastrophic Illness
(i.e., a patient file in the NHIRD), were extracted as the
research data sources. This study was approved by the
Institutional Review Board of Kaohsiung Medical University
Hospital, Kaohsiung, Taiwan (KMUH-IRB-20120047).
Study cohort
This cohort included women with newly diagnosed BC who
were prescribed HT at least once for >28 days of dispensed
days from 2003 to 2010 to allow for at least 1 year of follow-
up. All eligible patients were followed until the occurrence
of death or to the end of the study (December 2011).
Women with BC were identified by screening NHIRD and
the Registry for Catastrophic Illness via BC-related Inter-
national Classification of Diseases Revision 9 (ICD-9) codes
(174 for BC). The first BC diagnosis dates recorded from
2003 to 2010 were considered as disease index dates. Newly
diagnosed BC was defined if the patients did not have other
cancers (ICD-9 codes 140e208, except 174) or benign le-
sions (ICD-9 codes 210e239) recorded prior to the disease
index date. Furthermore, patients who had any non-HT-
covered period between two consecutive HT prescriptions
for >180 days during the study period were considered
interrupted cases and were excluded.
Prescribing pattern
Each patient’s HT prescriptions were followed from the first
prescription issued date between 2003 and 2010 (i.e., index
date of HT) to the final prescription date, death, or the end
of the study (December 31, 2011).
HT utilization patterns were categorized into five
groupsdtamoxifen only, switched from tamoxifen to AIs,
AIs only, switched from AIs to tamoxifen, and multiple
switches (switching > 1 time)dby the therapy they
received over the follow-up period. The “switching” be-
tween tamoxifen and AIs was defined when an alternative
HT was given for >84 days (estimated duration for 3
maximum refills: 28 days  3 refills) after a discontinuation
of the previous HT treatment course.
Measurement of medication possession ratio
Of those with persistence to HT, the individual’s MPR of HT
was calculated at the overall HT duration. MPR was calcu-
lated as dividing “total days of supply” by “prescription
duration” of HT. The prescription duration of HT was
identified as the duration between the first and the last
prescriptions plus the last prescription’s days of supply. The
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defining nonadherence, was used to categorize the patients
into two groups (i.e., adherence and nonadherence) [22].
Covariates
Patient age at BC diagnosis, baseline Charlson comorbidity
index (CCI) score, BC treatment strategies, HT utilization
patterns and prescriptions for managing the HT-related
adverse events (AEs) or concurrent symptoms of insomnia
and anxiety were also recorded as covariates in the analysis
models. The age of diagnosis was further categorized into
four groups: <50 years, 50e64 years, 65e69 years, and 70
years. Patient’s comorbidities recorded at the year prior to
BC diagnosis were identified and converted into a CCI score
[23,24], following which the patients were further catego-
rized into three groups (with CCI of 0, 1, or  2).
Patient’s BC treatment strategiesdsurgery (OP),
chemotherapy (CT), radiotherapy (RT), HT, or targeted
therapy (TT)dwere identified by corresponding codes for
medical orders and drugs, and dichotomized individually as
covariates. OPs, CTs, or RTs that occurred within 12 months
after the disease index date were considered as the pri-
mary BC treatment strategies. HT administered after OPTable 1 Patients’ characteristics in breast cancer women’s per
Characteristic Total Ad
Number of patients 32,311 31
Diagnosed age (y) 52.3  11.6 52
Diagnosed age groups (y)
<50 14,950 (46.3) 14
50e64 12,177 (37.7) 11
65e69 2202 (6.8) 21
70 2982 (9.2) 28
CCI score
0 22,628 (70.0) 21
1 6389 (19.8) 61
2 3294 (10.2) 31
Primary therapy
Mastectomy 21,219 (65.7) 21
BCS 9807 (30.4) 98
HT utilization pattern
Tamoxifen only 22,451 (69.5) 21
Tamoxifen to AIs 4436 (13.7) 42
AIs only 4048 (12.5) 37
AIs to tamoxifen 250 (0.8) 24
Multiple switches 1126 (3.5) 10
Patient had other adjuvant therapy
Chemotherapy 22,362 (69.2) 21
Radiotherapy 15,708 (48.6) 15
Target therapy 1638 (5.1) 15
HT-related side effects management
MSAEs (Yes) 4751 (14.7) 44
VMSs (Yes) 265 (0.8) 24
Insomnia (Yes) 2537 (7.9) 24
Anxiety (Yes) 2712 (8.4) 25
Data are presented as n (%) or mean  SD.
* Significant difference, p < 0.05.
AIs Z aromatase inhibitors; BCS Z breast-conserving surgery; C
HT Z hormone therapy; MSAEs Z musculoskeletal and joint symptomwas considered adjuvant HT; by contrast, HT administered
without any prior primary OP was recognized as primary HT.
The 2010 Taiwan Cancer Registry Annual Report showed
that 83% of women with surgery and HT were in stage II or
lower, and 51% of women with HT only were in stage III or
higher [25]. Therefore, we might assume that the adjuvant
and primary HT groups had different characteristics.
Medicines attempting to manage HT-related AEs or
concurrent symptoms of insomnia and anxiety were used as
surrogate indicators to identify relevant AEs associated
with tamoxifen or AI treatment. Such prescriptions issued
with HT at the same outpatient visit during the windows of
the 4th month to the 12th month in the 1st year of HT were
identified, including anti-inflammatory agents and anal-
gesia for musculoskeletal and joint symptoms (MSAEs), an-
tidepressants and gabapentin for vasomotor symptoms
(VMSs), hypnotics and sedatives for insomnia, and anxio-
lytics for anxiety.
Data analysis
Descriptive statistics were used to report the demographic
data of participants. Differences between treatments and
adherences versus nonadherence were evaluated using thesistence to hormone therapy.
juvant HT Primary HT p
,026 (96.0) 1285 (4.0)
.4  11.6 51.5  11.1 0.0056*
,321 (46.2) 629 (49.0) 0.0245*
,700 (37.7) 477 (37.1)
13 (6.8) 89 (6.9)
92 (9.3) 90 (7.0)
,704 (70.0) 924 (71.9) 0.1827
41 (19.8) 248 (19.3)
81 (10.3) 113 (8.8)
,219 (68.4)
07 (31.6)
,644 (69.8) 807 (62.8) <0.0001*
96 (13.9) 140 (10.9)
63 (12.1) 285 (22.2)
1 (0.8) 9 (0.7)
82 (3.5) 44 (3.4)
,637 (69.7) 725 (56.4) <0.0001*
,213 (49.0) 495 (38.5) <0.0001*
28 (4.9) 110 (8.6) <0.0001*
95 (14.5) 256 (19.9) <0.0001*
6 (0.8) 19 (1.5) 0.0076*
38 (7.9) 99 (7.7) 0.8410
93 (8.4) 119 (9.3) 0.2526
I Z confidence interval; CCI Z Charlson Comorbidity Index;
s; OR Z odds ratio; VMSs Z vasomotor symptoms.
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continuous variables.
Logistic regression was used to evaluate the odds ratios
(ORs) of nonadherence in HT persistent patients while
adjusting for the covariates, including age of diagnosis, CCI
score, BC treatment strategies, HT utilization patterns,
management of HT-related AE or concurrent symptoms,
insurance income, registry areas of NHI divisions, HT pre-
scription duration, and year of HT initiation. The results
were presented in adjusted ORs and 95% confidence in-
tervals (CIs). All analyses were conducted using SAS version
9.3 (SAS Institute, Inc., Cary, NC, USA).Results
Patient characteristics
A total of 32,311 women with newly diagnosed BC who had
persistence to HT (mean age, 52.3  11.6 years) were iden-
tified. Their total follow-up time was 138,854 patient-years
(median follow-up time, 4.2 years). Among these patients,Table 2 Patients’ characteristics and risk factors of nonadhere
Characteristic Adherence Nonadherenc
Number of patients 26,179 (84.4) 4847 (15.6)
Diagnosed age groups (y)
<50 11,699 (81.7) 2622 (18.3)
50e64 10,089 (86.2) 1611 (13.8)
65e69 1837 (86.9) 276 (13.1)
70 2554 (88.3) 338 (11.7)
CCI score
0 18,159 (83.7) 3545 (16.3)
1 5284 (86.0) 857 (14.0)
2 2736 (86.0) 445 (14.0)
Primary therapy
Mastectomy 17,973 (84.7) 3246 (15.3)
BCS 8206 (83.7) 1601 (16.3)
HT utilization pattern
Tamoxifen only 17,843 (82.4) 3801 (17.6)
Tamoxifen to AIs 3888 (90.5) 408 (9.5)
AIs only 3303 (87.8) 460 (12.2)
AIs to tamoxifen 216 (89.6) 25 (10.4)
Multiple switches 929 (85.9) 153 (14.1)
Patient had other adjuvant therapy
Chemotherapy (Ref: No) 18,191 (84.1) 3446 (15.9)
Radiotherapy (Ref: No) 12,830 (84.3) 2383 (15.7)
Target therapy (Yes) 1195 (78.2) 333 (21.8)
HT related side effects management
MSAEs (Yes) (Ref: No) 3769 (83.9) 726 (16.2)
VMSs (Yes) (Ref: No) 201 (81.7) 45 (18.3)
Insomnia (Yes) (Ref: No) 2052 (84.2) 386 (15.8)
Anxiety (Yes) (Ref: No) 2204 (85.0) 389 (15.0)
Data are presented as n (%).
* Significant difference, p < 0.05.
AIs Z aromatase inhibitors; BCS Z breast-conserving surgery; C
MSAEs Z musculoskeletal and joint symptoms; NHI Z National Healt
a Odds ratios and 95% confidence intervals (95% CI) were adjusted
groups, registered areas of NHI divisions, year of HT initiation, and HT
a limited sample size.46.3% were diagnosed when they were aged 50 years, and
they predominantly had a CCI score of 0 (70.0%). During the
HT utilization period (mean, 2.7  1.9 years), most patients
received only tamoxifen (69.5%); aminority received only AIs
(12.5%); and 14.7% of the cohort received pharmacologic
management for HT-related side effects of MSAEs (Table 1).
Ninety-six percent of the women received surgery during
the 1st year of BC diagnosis. Compared with the adjuvant
HT group, patients in the primary HT group had a higher
proportion of age at diagnosis younger than 50 years (49.0%
vs. 46.2%), receiving AIs only (22.2% vs. 12.1%), TT (8.6% vs.
4.9%), and treatments for MSAEs (19.9% vs. 14.5%) and VMSs
(1.5% vs. 0.8%; Table 1).
Patient characteristics of adherence and
nonadherence and risks of nonadherence in
adjuvant HT
Of the 31,026 women, those who had adjuvant HT (mean age
of diagnosis, 52.4  11.6 years), 15.6% had nonadherence
(MPR<80%) toHT (Table2). Therewerehigherproportions of
patients thatwere diagnosedwith BC at a younger age (18.3%nce in adjuvant hormone therapy users.
e p Adjusted OR (95% CI)a p
<0.0001* 1.00
0.80 (0.75e0.86) <0.0001*
0.73 (0.63e0.84) <0.0001*
0.62 (0.54e0.71) <0.0001*
<0.0001* 1.00
0.93 (0.85e1.01) 0.0674
0.97 (0.87e1.09) 0.6001
0.0205* 1.00
1.09 (1.00e1.19) 0.0496*
<0.0001* 1.00
0.61 (0.54e0.68) <0.0001*
0.72 (0.65e0.81) <0.0001*
0.62 (0.41e0.95) 0.0277*
0.96 (0.81e1.15) 0.6838
0.0251* 1.10 (1.02e1.19) 0.0141*
0.8421 0.96 (0.89e1.04) 0.3657
<0.0001*
0.2909 1.09 (0.99e1.19) 0.0756
0.2468 1.27 (0.90e1.78) 0.1702
0.7658 1.03 (0.91e1.16) 0.6714
0.3633 0.95 (0.84e1.07) 0.3634
CI Z Charlson Comorbidity Index; HT Z hormone therapy;
h Insurance; OR Z odds ratio; VMSs Z vasomotor symptoms.
for all listed variables in the table as well as insurance income
prescription duration. Targeted therapy was not included owing to
332 K.-P. Hsieh et al.at< 50 years vs. 11.7% at> 70 years) and had tamoxifen only
(17.6% in tamoxifen only vs. 12.2% in AIs only) in the non-
adherence group. They were also less likely to have received
other forms of adjuvant therapy (CT, pZ 0.0251), and (TT,
p < 0.0001) when compared to the adherence group.
After adjusting the covariates, younger age of diagnosis
(<50 years), breast-conserving surgery (compared to mas-
tectomy; OR Z 1.09; 95% CI, 1.00e1.19), CT (OR Z 1.10;
95% CI, 1.02e1.19), and treatment with tamoxifen only
(compared to the other four HT utilization patterns) were
significantly associated with higher chance of non-
adherence (Table 2).
Patient characteristics of adherence and
nonadherence and risks of nonadherence in
primary HT
As shown in Table 3, there were no statically significant
differences between each covariate, except for the expe-
rience of MSAEs (p Z 0.0132). However, there were higher
proportions of women in the nonadherence group who had
a younger age at diagnosis (<50 years), higher CCI score
(2), and were receiving AIs first followed by a switch to
tamoxifen. After adjusting covariates, younger age ofTable 3 Patients’ characteristics and risk factors of nonadhere
Characteristic Adherence Nonadhe
Number of patients 984 (76.6) 301 (23
Diagnosed age groups
<50 y 471 (74.9) 158 (25
50e64 y 367 (76.9) 110 (23
65e69 y 72 (80.9) 17 (19
70 74 (82.2) 16 (17
CCI score
0 715 (77.4) 209 (22
1 187 (75.4) 61 (24
2 82 (72.6) 31 (27
HT utilization pattern
Tamoxifen only 624 (77.3) 183 (22
Tamoxifen to AIs 112 (80.0) 28 (20
AIs only 205 (71.9) 80 (28
AIs to tamoxifen 6 (66.7) 3 (33
Multiple switches 37 (84.1) 7 (15
Patient had other adjuvant therapy
Chemotherapy (Yes) (Ref: No) 548 (75.6) 177 (24
Radiotherapy (Yes) (Ref: No) 390 (78.8) 105 (21
Target therapy (Yes) 77 (70.0) 33 (30
HT related side effects management
MSAEs (Yes) (Ref: No) 181 (70.7) 75 (29
VMSs (Yes) (Ref: No) 13 (68.4) 6 (31
Insomnia (Yes) (Ref: No) 73 (73.7) 26 (26
Anxiety (Yes) (Ref: No) 95 (79.8) 24 (20
Data are presented as n (%).
* Significant difference, p < 0.05.
AIsZ aromatase inhibitors; CCIZ Charlson comorbidity index; HTZ
NHI Z National Health Insurance; OR Z odds ratio; VMSs Z vasomot
a Odds ratios and 95% confidence intervals (95% CI) were adjusted
groups, registered areas of NHI divisions, year of HT initiation, and HT
a limited sample.diagnosis (<50 years) and experienced MSAEs were the only
two risk factors for nonadherence in primary HT group
(Table 3).Discussion
To our knowledge, this population-based study is the first to
evaluate the HT patterns and risks to HT nonadherence
among women with BC using claim-based dataset in Asia.
Women with BC with persistence to HT had 15.6% and 23.4%
nonadherence rates to HT in the adjuvant and primary HT
groups, respectively, which may cause a suboptimal ther-
apeutic effect in BC women.
In our study, younger age (<50 years) was associated
with a lower adherence, which is consistent with other
cohort studies in women with BC [19,26,27]. HT non-
adherence rates are generally higher when comparing older
[26,28e31] with younger [26,32e34] BC patients, although
current evidence is still inconclusive owing to the various
age ranges included in the literature. Partridge et al. [19]
and Atkins and Fallowfield [35] reported that younger
women and those younger than 57.6 years were often
intentionally nonadherent with their medication, and their
refusal to adhere to treatment regimens may bence in primary hormone therapy users.
rence p Adjusted OR (95% CI)a p
.4)
.1) 0.3118 1.00
.1) 0.84 (0.62e1.14) 0.2711
.1) 0.55 (0.30e1.01) 0.0543
.8) 0.53 (0.28e0.99) 0.045*
.6) 0.4638 1.00
.6) 1.14 (0.81e1.60) 0.4615
.4) 1.48 (0.92e2.38) 0.1044
.7) 0.1664 1.00
.0) 0.88 (0.55e1.43) 0.6152
.1) 1.22 (0.83e1.79) 0.3173
.3) 1.62 (0.38e6.93) 0.5160
.9) 0.81 (0.34e1.91) 0.6219
.4) 0.3405 0.87 (0.62e1.22) 0.4264
.2) 0.1383 0.77 (0.58e1.03) 0.0744
.0) 0.0886
.3) 0.0132* 1.44 (1.02e2.03) 0.038*
.6) 0.3978 1.11 (0.39e3.10) 0.8499
.3) 0.4876 1.14 (0.69e1.89) 0.6091
.2) 0.3786 0.67 (0.41e1.12) 0.1246
hormone therapy; MSAEsZ musculoskeletal and joint symptoms;
or symptoms.
for all listed variables in the table as well as insurance income
prescription duration. Targeted therapy was not included owing to
Hormone therapy nonadherence and risks 333attributable to a lack of interest and a dislike of taking
medicines. These previous studies did not have large pro-
portions of young patients (age at diagnosis, <50 years) as
compared to our cohort, which showed that 46.3% were
from a younger population. Our results indicated that
nonadherence was associated with younger age of diag-
nosis, and therefore the impact might be greater in Asian
populations given the relatively younger age distribution of
BC in this group.
If the benefits of drugs are not immediately observed,
adherence is less likely to be achieved, particularly in
women with BC on 5-year HT, which does not offer a
guarantee of recurrence-free survival but does cause AEs
[35]. Both tamoxifen and AIs are generally well-tolerated
medications. Some studies indicate that AEs are the
major reason for tamoxifen interruption, particularly dur-
ing the 1st year of HT, as reported by patients’ or treating
physicians’ surveys [28,31,35e37]. In our study, we found
that MSAEs might have been a negative factor associated
with nonadherence (Table 3). Up to 70% of women with BC
reported experiencing hot flashes while receiving HT [38].
However, in our population the median menopausal age is
similar to BC diagnosed age; hot flash may not be addressed
as an HT-related AE by patients or physicians. Because
these AEs (e.g., MSAEs, insomnia, and anxiety) may imme-
diately affect the patient’s quality of life, these findings
could provide information to health care providers to in-
crease the adherence of HT in women with BC.
CTwas associated with increasing nonadherence to HT in
this study. A possible explanation for this might be that, for
the psychological adjustment in self-perception among in-
dividuals who are disease-free after surgery and chemo-
therapy, they may not want to continue seeing themselves
as being ill, whereas taking pills is a reminder of this situ-
ation [35]. Another possible explanation for this is that they
have a perception that the most important adjuvant sys-
temic therapy is CT (an injection as opposed to HT, which is
a tablet). As such, following completion of CT, they may see
that continuation of HT may be of less importance.
The latest systemic review from Ayres et al. [9]
demonstrated that most published studies were evaluated
primarily in adjuvant HT. We were able to identify a group
of primary HT (non-OP) in our study. The primary HT group
had higher proportions of receiving AIs only and TT (Table
1). Women in the primary HT group had a higher chance
of experiencing AEs of MSAEs and VMSs compared to women
in the adjuvant HT group (Table 1), and were associated
with increasing nonadherence risk (Table 3). In the adju-
vant HT group, women with younger age at diagnosis,
receiving breast-conserving surgery, AIs, and CT had a
higher risk for nonadherence. Compared to adjuvant HT,
only young age and experience of MSAEs were identified as
risk factors for nonadherence in primary HT.
We recognize that there are limitations to the study.
First, NHIRD contains only information for reimbursement
purposes. Therefore, information on disease status was not
available. Because surgery is recommended as a standard
initial treatment for stages IeII BC in line with the National
Comprehensive Cancer Network guideline [39], and >90% of
women with BC who received surgery were at stages IeIII in
Taiwan, based on the clinical guidelines and practice pat-
terns in Taiwan [25], our study attempted to use OP or non-OP as an indicator to classify BC stages. Second, we might
have underestimated the rate of HT-related AEs, because
the database may only contain severe, intolerable, or life-
threatening AEs recorded by clinicians rather than patient-
reported issues [40]. In addition, the indication of gaba-
pentin for VMSs or cancer-related pain may be over-
estimated by our definition because gabapentin can also be
prescribed for pain relief. We also might have over-
estimated the rate of muscle pain caused by HT, because it
may be caused by the disease itself; however, muscle pain
still can affect the patient’s quality of life. The possibilities
of under- or overestimation could happen equally to both
adherent and nonadherent groups, and hence their effects
on our conclusion would be limited. Lastly, the majority of
our cohort is composed of Chinese individuals, which might
limit the generalizability of these findings beyond this
population with other races in Asia.
In summary, we found that nonadherence rates to HT
were high and associated with younger diagnosed age
(<50 years), and experiencing AEs in a predominantly
ethnic Chinese women population-based database. These
findings also inform physicians and pharmacists of the
predictive risks of HT nonadherence. To improve adherence
of HT, further research is needed to explore issues
impeding HT adherence in patients with these
characteristics.
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